Form 3 Jones David Scott

Initial statement of beneficial ownership of securities

Published: 2019-06-12 16:34:26
Submitted: 2019-06-12
Period Ending In: 2019-06-10
primarydocument.html PRIMARY DOCUMENT


SEC FORM 3

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Jones David Scott

(Last) (First) (Middle)
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET

(Street)
WATERTOWN MA 02472

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/10/2019
3. Issuer Name and Ticker or Trading Symbol
EyePoint Pharmaceuticals, Inc. [ EYPT ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP & Chief Commercial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney
No securities are beneficially owned.
Ron Honig, Attorney-in-Fact for David Scott Jones 06/12/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
1
primarydocument.xml PRIMARY DOCUMENT
Schema Version:
X0206
Document Type:
3
Period Of Report:
2019-06-10
No Securities Owned:
1

Issuer

Issuer Cik
0001314102
Issuer Name
EyePoint Pharmaceuticals, Inc.
Issuer Trading Symbol
EYPT

Reporting Owner

Reporting Owner Id

Rpt Owner Cik
0001779458
Rpt Owner Name
Jones David Scott

Reporting Owner Address

Rpt Owner Street1
C/O EYEPOINT PHARMACEUTICALS, INC.
Rpt Owner Street2
480 PLEASANT STREET
Rpt Owner City
WATERTOWN
Rpt Owner State
MA
Rpt Owner Zip Code
02472

Reporting Owner Relationship

Is Director
false
Is Officer
true
Is Ten Percent Owner
false
Is Other
false
Officer Title
SVP & Chief Commercial Officer
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Owner Signature

Signature Name
Ron Honig, Attorney-in-Fact for David Scott Jones
Signature Date
2019-06-12
poa_scottjones2.txt POA FOR SCOTT JONES
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poa_scottjones2.txt
<DESCRIPTION>POA FOR SCOTT JONES
<TEXT>
Exhibit 24
POWER OF ATTORNEY

	Know all by these presents, that the undersigned hereby
constitutes and appoints the President and Chief Executive Officer,
the Chief Financial Officer, and the Senior Vice President, General
Counsel and Secretary of EyePoint Pharmaceuticals, Inc. (the
"Company"), signing singly, and with full power of substitution,
each as the undersigned's true and lawful attorney-in-fact to:

(1)	execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or a director of the
Company, the undersigned's application for EDGAR Access with the
United States Securities and Exchange Commission (Form ID
application);

(2)	execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or a director of the
Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934 and the rules thereunder;

(3)	do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to (A) complete and
execute any such Forms 3, 4, or 5, (B) complete and execute any
amendment or amendments thereto, and (C) timely file such form with
the United States Securities and Exchange Commission and any stock
exchange or similar authority; and

(4)	take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-in-fact,
may be of benefit to, and in the best interest of, or legally
required by, the undersigned, it being understood that the
documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such attorney-
in-fact may approve in such attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-
fact full power and authority to do and perform any and every act
and thing whatsoever requisite, necessary, or proper to be done in
the exercise of any of the rights and powers herein granted, as
fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such attorney-
in-fact, or such attorney-in-fact's substitute or substitutes,
shall lawfully do or cause to be done by virtue of this Power of
Attorney and the rights and powers herein granted.

	The undersigned acknowledges that the foregoing attorney-
in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of
the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934.

	This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to file Forms 3,
4 and 5 with respect to the undersigned's holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of this 12th day of June, 2019.

					/s/ David Scott Jones
					Signature
					    David Scott Jones
					Print Name



</TEXT>
</DOCUMENT>
Additional Files
FileSequenceDescriptionTypeSize
0001562180-19-003506.txt   Complete submission text file   6786
$EYPT

© 2019 SEC.report
SEC CFR Title 17 of the Code of Federal Regulations.